Coya Therapeutics reported a significant improvement in its FY23 financial results with EPS improving to $(0.79) from $(4.73) YoY. The company also highlighted a collaboration revenue of $6M and an increase in cash and cash equivalents to $32.6 million. A notable part of their income includes a $7.5 million upfront payment from Dr. Reddy's for the COYA 302 licensing arrangement. R&D expenses rose to $5.5 million, primarily due to increased preclinical and internal R&D expenses, while G&A expenses increased to $7.8 million due to higher personnel and professional fees. The net loss narrowed to $8.0 million from $12.2 million YoY.